Analyst Ratings For AnaptysBio (NASDAQ:ANAB)
Today, Royal Bank Of Canada raised its price target on AnaptysBio (NASDAQ:ANAB) to $79.00 per share.
There are 6 buy ratings on the stock.
The current consensus rating on AnaptysBio (NASDAQ:ANAB) is Buy (Score: 3.00) with a consensus target price of $57.50 per share, a potential 18.34% downside.
Some recent analyst ratings include
- 9/12/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 7/10/2017-Robert W. Baird initiated coverage with a Outperform rating.
- On 8/21/2017 Holdings A/S Novo, Major Shareholder, sold 356,300 with an average share price of $21.10 per share and the total transaction amounting to $7,517,930.00. View SEC Filing
- On 8/15/2017 Holdings A/S Novo, Major Shareholder, sold 178,600 with an average share price of $21.16 per share and the total transaction amounting to $3,779,176.00. View SEC Filing
- On 8/7/2017 Holdings A/S Novo, Major Shareholder, sold 491,294 with an average share price of $21.12 per share and the total transaction amounting to $10,376,129.28. View SEC Filing
- On 8/3/2017 Holdings A/S Novo, Major Shareholder, sold 70,706 with an average share price of $23.31 per share and the total transaction amounting to $1,648,156.86. View SEC Filing
- On 7/26/2017 Ventures Vii L P Avalon, Major Shareholder, sold 37,040 with an average share price of $24.35 per share and the total transaction amounting to $901,924.00. View SEC Filing
- On 1/31/2017 Healthcare Vii L.P. Frazier, Major Shareholder, bought 400,000 with an average share price of $15.00 per share and the total transaction amounting to $6,000,000.00. View SEC Filing
- On 1/31/2017 Nicholas Lydon, Director, bought 16,666 with an average share price of $15.00 per share and the total transaction amounting to $249,990.00. View SEC Filing
Recent Trading Activity for AnaptysBio (NASDAQ:ANAB)
Shares of AnaptysBio closed the previous trading session at with shares trading hands.